The Sanford PLEDGE Study

Integrating Screening into Routine Pediatric Care Across a Health System

Kurt J. Griffin PhD, MD

Todd and Linda Broin Chair for Diabetes Research
Director of Clinical Trials
Sanford Health
Sioux Falls, South Dakota

6th Childhood Diabetes Prevention Symposium Barbara Davis Center 10 November 2023







Past Screening Efforts Miss Most People at Risk

Diabetes TrialNet

- Screen for autoantibodies in family members of people with T1D
- ~250,000 people screened over 18 years

BUT:

- 92% who will get T1D have no family history
- Not eligible for TrialNet screening
- Expect 1 in 200 people





Sanford PLEDGE: General Population Screening

Novel, Pragmatic Design:


- Minimize burden on:

Providers & Staff

Families

Research Coordinators

- Integrated into routine clinic visits
- Leverage existing Epic electronic record system and
- MyChart patient messaging for enrollment & questionnaires
- Economic analyses and modeling
- No cost to families







Goals

- Prevent initial diabetic ketoacidosis
- Identify patients for possible intervention:
 - Teplizumab when appropriate
 - Stage 1 / 2 intervention trials
- Generate evidence to support including T1D screening
 - Demonstrate feasibility of integration into routine pediatric care
 - Prospective validation of GRS and assessment of utility to focus screening
 - Assess cost effectiveness of general population screening



PLEDGE Overview of Procedures


Entry before 6th birthday OR once 9 -16 y.

Genetic Risk Score
GRS2 Once at study entry
(blood spot; can be with Newborn Screening)

Anxiety Survey
Entry & Annually

T1D AutoAb

Celiac Testing







PLEDGE Overview of Procedures

Entry before 6th birthday OR once 11-16 y.

Genetic Risk Score
GRS2 Once at study entry
(blood spot; can be with Newborn Screening)

Anxiety Survey
Entry & Annually

T1D AutoAb

Celiac Testing

Birth 2 years 5 years






Antibody Screening at ~2, ~ 5, and 9-16 years of age



PLEDGE Overview of Procedures




GRS2 at study entry

- -SNP-based risk score for T1D and Celiac autoimmunity
- Can enroll before birth and collect with newborn screens




Innovation and Infrastructure



TYPE 1 DIABETES AND CELIAC

Epic Notifications

"BPA" [light] in Storyboard






"Patient Chart Advisory"


- Appears on opening chart
- Reminder to consider T1D
- Provides guidance
- Does not slow work
- Less intrusive than BPA




Expansion and Enrollment

Now Open at every primary care clinic in Sioux Falls and Fargo Still ahead of planned enrollment and budget





Expansion and Enrollment



TYPE 1 DIABETES AND CELIAC

Race

Caucasian 2344
African American 75
Native American 64
Asian 31
HI/Pacific Island 1


Ethnicity

Not Hispanic 2390 Hispanic 117 Unknown 22

<u>Sex</u>

Male 1262 Female 1273

Age at Entry (with collection)



Screening Results

Celiac Disease:

Positive Screens 92 Previously known CD Repeat Testing Pending Persistent positives (to GI) 45


T1D:

<u> </u>		
Positive Screens		124
Repeat Testing Pending		2
Persistent positive		36
Single Antibody		25
RBA-only:	6	
"High Affinity" RBA & ECL:	11	
Multiple Antibodies		11
2 Antibodies	5	
3 Antibodies	2	
4 Antibodies	4	
Clinical Care		3

DKA at Diagnosis 0 ... so far



PLEDGE Screening






PLEDGE Screening

PLEDGE Monitoring

- Separate Protocol and Consent after confirmation of persistent antibody.
- Tailor extent and frequency to expected risk
- 48 Children in enrolled







Thank you

All the families who participate

The Sanford Project Team

Ann Mays

Magdalena Skon

Lana Baerenwald

Vanessa Williams

Mary Berg

Connie Hoffman

Staci Schwingler

Clinical Providers

Luis Casas

Stephanie Hanson

John Shelso

Rashmi Jain

Benjamin Hoag

Jennifer Richstmeier

Parent Representatives

Kristin Little

Holly McMahon

Sanford Health Plan

Emily Griese

Collaborators & Advisors

Bill Hagopian

Richard Oram

Marian Rewers